Cohort study on the natural history of Parkinson's disease in France
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
This study is trying to understand how Parkinson's disease changes over time by collecting information and blood samples from patients in France to help find new ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30000 (estimated) |
| Ages | 10 Years and up |
| Sex | All |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris) |
| Trial ID | NCT04888364 on ClinicalTrials.gov |
What this trial studies
The NS-PARK cohort aims to describe the natural history of Parkinson's disease (PD) and develop patient stratification models based on the disease's pathophysiological mechanisms. Conducted across expert centers in France, the study collects standardized demographic, diagnostic, and clinical data, including motor and non-motor symptoms, which are updated at each patient visit. Blood samples are also collected for genetic testing and biobanking. This longitudinal cohort will facilitate the understanding of PD progression and support the discovery of new genetic factors influencing the disease.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Parkinson's disease or related parkinsonian syndromes, as well as those at risk of developing PD.
Not a fit: Patients who do not have a diagnosis of Parkinson's disease or related syndromes and are not at risk for the disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with Parkinson's disease.
How similar studies have performed: Other studies have shown success in understanding Parkinson's disease through cohort approaches, making this a promising continuation of similar research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Parkinson's disease according to UK PD brain bak criteria * OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom * OR Subjects at risk of PD defined as : No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015) AND for all participants * Affiliated to social security * Age \> 10 years Exclusion Criteria: * Subject under legal protection * Subject who do not consent to the research * for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
Where this trial is running
Paris
- Centre 01 Paris — Paris, France (Recruiting)
Study contacts
- Principal investigator: Jean Christophe MD CORVOL, PU-PH — Umrs 1127
- Study coordinator: Jean Christophe MD CORVOL, PU-PH
- Email: jean-christophe.corvol@aphp.fr
- Phone: 33 1 42 16 57 66
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.